An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thromboythemia Myelofibrosis and Post Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50x109 /L to 100 x 109/L
Conditions
Post Essential Thromboythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis | Primary Myelofibrosis
Trial Phase
Trial Purpose and Description
Trial Purpose
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Eligibility Criteria
- Sponsor:
- Incyte Corporation
- Dates:
- January 2012
- Last Updated:
- Study HIC#:
- 1107008805
Clinicaltrials.gov ID: Yale4011303
